Development of
BCR-ABL1
-positive ɤδ T-cell leukemia after treatment for thymoma type B1
Leuk Lymphoma
.
2021 May;62(5):1259-1262.
doi: 10.1080/10428194.2020.1856834.
Epub 2020 Dec 7.
Authors
Toshiki Terao
1
,
Hiroya Ashimine
2
,
Naoko Tsuyama
3
,
Daisuke Ikeda
1
,
Ayumi Kuzume
1
,
Rikako Tabata
1
,
Takafumi Tsushima
1
,
Daisuke Miura
1
,
Kentaro Narita
1
,
Masami Takeuchi
1
,
Kengo Takeuchi
3
4
,
Kosei Matsue
1
Affiliations
1
Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Centre, Chiba, Japan.
2
Division of Oncology, Department of Internal Medicine, Kameda Medical Centre, Chiba, Japan.
3
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
4
Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
PMID:
33284042
DOI:
10.1080/10428194.2020.1856834
No abstract available
Publication types
Letter
MeSH terms
Fusion Proteins, bcr-abl / genetics
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
Leukemia, T-Cell*
Thymoma* / therapy
Thymus Neoplasms* / genetics
Thymus Neoplasms* / therapy
Substances
Fusion Proteins, bcr-abl